Lead, reproduction and development.

C Winder

PubMed · 8247405

Lead, reproduction and development.

Abstract

Lead remains a significant occupational health and public health problem. Excessive lead exposure, not only to men exposed at work, but also from lead based paint in older housing and from soil, still persists in the community. From the perspective of human reproduction, lead is known to cause a number of adverse outcomes in both men and women. Reported effects in men include reduced libido, effects on spermatogenesis (reduced motility and numbers, increased normal morphology), chromosomal damage, infertility, abnormal prostatic function and changes in serum testosterone. Most of these effects have been seen in lead exposed workers, and some are at levels presently considered 'acceptable'. Effects in women include infertility, miscarriage, premature membrane rupture, pre-eclampsia, pregnancy hypertension and premature delivery. Again, recent research findings indicate that lead may be toxic at levels previously thought to have no effect. The evidence implicating a possible teratogenic effect of lead is much less clear. While there is some indication of an association of lead with the production of anomalies, any dose-response relationship or causal mechanism has yet to be established. Therefore, while lead does affect human reproduction, the question: Is lead a teratogen? is yet to be answered.

Explore related subjects

Abnormalities, Drug-Induced Animals Cells, Cultured Dose-Response Relationship, Drug Female Humans Lead Poisoning Male Nervous System Reproduction Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

C Winder. Lead, reproduction and development.. https://pubmed.ncbi.nlm.nih.gov/8247405/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Risk of drug-induced congenital defects.

Defects attributable to drug therapy represent about 1% of congenital defects of known aetiology. This means that a precautionary attitude and correct use of drugs in fertile, and especially pregnant, women is a feasible form of prevention. Drugs currently in use with proven teratogenic effect number approximately 25, but new pharmaceutical drugs are constantly in preparation. Recognition of a drug-induced teratogenic effect is a complex procedure taking into account not only experimental animal data but also experience in humans. Considering that 40% of pregnancies are not planned, it follows that any drug with known or suspected teratogenic potential must be used only under strict medical control. Also, adequate knowledge on potential teratogenicity of a drug permits modification of therapy before conception. It goes without saying that any drug should be used during pregnancy only if it is essential, and it would be prudent to use only those where adequate information is provided and prior clinical experience is available. Teratology Information Services can assist both physicians and patients when any doubt exists.

Abnormalities, Drug-Induced↗

PubMed2004

Endocrine-disrupting activity in carbendazim-induced reproductive and developmental toxicity in rats.

This study was designed to investigate the endocrine-disrupting activity of carbendazim-induced reproductive and developmental toxicity in Sprague-Dawley rats treated orally with the fungicide. Cotreatment of male rats with 675 mg/kg carbendazim and 50 or 100 mg/kg flutamide, an androgen receptor antagonist, once daily for 28 d blocked decrease of testis weight induced by treatment with carbendazim alone. The cotreatment prevented losses of spermatozoa and cell morphology and decrease of sperm concentration induced by carbendazim. Premating treatment of male and female rats with 200 mg/kg carbendazim for 28 d produced androgenic effects including incomplete development of uterine horn, enlargement of uretha, absence of vagina, and induction of seminal vesicles in female offspring, without marked effects in male offspring. Premating treatment with 100mg/kg benomyl, the parent compound of carbendazim, resulted in incomplete development of uterine horn and absence of vagina in female offspring and produced testis and epidydimis atropy in male offspring. Treatment of male rats with 25, 50, 100, 200, 400, and 800 mg/kg carbendazim for 56 d produced dose-dependent increases of androgen receptor concentrations in testis and epididymis. Additions of 5, 50, and 500 microM carbendazim to testis extract from untreated rats replaced binding of [3H]-5 alpha-dihydrotestosterone to androgen receptor in a concentration-dependent manner. The present study demonstrates that reproductive toxicity induced by carbendazim is blocked by an androgen receptor antagonist in male rats and developmental toxicity of the fungicide shows androgenic properties in female offspring. These results suggest that androgen- and androgen receptor-dependent mechanisms are possibly involved in carbendazim-induced toxicity.

Abnormalities, Drug-Induced↗

PubMed2004

Prenatal toxicity of cyanide in goats--a model for teratological studies in ruminants.

Although exposure to cyanogenic plants or cyanide during pregnancy has adverse effects, no teratological study with cyanide has been conducted in goats or any other ruminant. The objective of the present study was to evaluate the effects of the maternal exposure to potassium cyanide (KCN) during pregnancy on both dams and offspring and furthermore, to develop a model for prenatal toxicological studies in ruminants. Twenty-six pregnant goats were allocated into four groups and given 0, 1.0, 2.0, or 3.0mg KCN/kg body weight per day orally (administered via twice-daily gavage) from Day 24 of pregnancy to term. However, one control dam and another from the 3.0mg KCN/kg per day group were sacrificed on Day 120. At birth, the kids were examined carefully for gross abnormalities. Three months after birth, the male kids and one dam from each group were sacrificed for histopathological study. Although clinical signs of poisoning were observed in dams, cyanide treatment did not alter the length of gestation or the number of live kids. Two prognata kids were born in the 3.0mg KCN/kg group, and one dam from the same group aborted two fetuses. There were histological lesions only in the KCN-treated dam (and its fetuses) sacrificed on Day 120; these consisted of an increased number of resorption vacuoles of thyroid follicular colloid, and status spongiosis of nervous white matter. This study proposes a new animal model for teratogenic trials that could be important to evaluate the effects of chemicals throughout pregnancy in goats and potentially other ruminants.

Abnormalities, Drug-Induced↗